Ignite Creation Date:
2024-05-06 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 12:48 PM
Study NCT ID:
NCT03566485
Status:
TERMINATED
Last Update Posted:
2021-08-11
First Post:
2018-06-11
Brief Title:
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Vanderbilt-Ingram Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HER2Neu Negative |
| Stage III Breast Cancer |
| Stage IIIA Breast Cancer |
| Stage IIIB Breast Cancer |
| Stage IIIC Breast Cancer |
| Stage IV Breast Cancer |
| Estrogen Receptor-positive |
Keywords: